Peripheral Nerve Block Compared to Intra-articular Injection for TAA Post-operative Pain

NCT ID: NCT03674905

Last Updated: 2018-09-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-29

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ankle arthritis is associated with debilitating pain and chronic disability. For the treatment of severe ankle arthritis, total ankle arthroplasty (TAA) is one treatment option. Postoperative pain management in joint arthroplasty is an ongoing and relevant issue. The purpose of this study is to examine if differences exist in postoperative pain control, overall patient satisfaction, and use of narcotics using an intra-articular injection in the operating room compared with a peripheral nerve block in patients undergoing TAA.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a two-arm, prospective, randomized, controlled clinical study. Use of intra-articular injections in TAA are not widely reported in literature; however, they are commonly used during total knee arthroplasty's (TKAs). The purpose of this study is to examine if differences exist in postoperative pain control, overall patient satisfaction, and use of narcotics using the intra-articular injection compared with a peripheral nerve block in patients undergoing TAA. Results will contribute to the literature for the best surgical practice for pain management following a TAA for ankle arthritis.

Patients will be randomized to receive one of the following interventions for pain control in the operating room:

1. Intra-articular Injection
2. Preoperative Peripheral Nerve Block:

The study aims are:

* Aim 1: Determine if intra-articular injection as source of pain control for TAA lowers postoperative pain as measured by self-reported narcotic use and pain vs. the peripheral nerve block.
* Aim 2: Evaluate differences in functional outcomes and health related quality of life between intra-articular injections and peripheral nerve block as reported by pre- and post-operative patient questionnaires

Patients who consent to participate will complete study activities pre-operatively, and at 2 weeks, 6 weeks, and 3 months post-operatively.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ankle Arthritis Ankle Arthropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intra-articular injection

Intra-articular injection at the completion of TAA procedure.

Group Type OTHER

Intra-articular injection

Intervention Type PROCEDURE

Intra-articular injection at the completion of TAA procedure.

Peripheral nerve block

Pre-operative peripheral nerve block.

Group Type OTHER

Peripheral nerve block

Intervention Type PROCEDURE

Pre-operative peripheral nerve block.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intra-articular injection

Intra-articular injection at the completion of TAA procedure.

Intervention Type PROCEDURE

Peripheral nerve block

Pre-operative peripheral nerve block.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient is 40 - 80 years old
* Patient is having a primary, unilateral TAA
* Patient has signed the current, Institutional Review Board approved informed consent document

Exclusion Criteria

* Patient has untreated endocrine disease
* Patient has uncontrolled diabetes; lab result of hemoglobin A1c level \> 8.0 mg/dL
* Patient has significant heart, liver, kidney or respiratory disease
* Patient has peripheral vascular disease
* Patient has active cancer
* Patient has current history of narcotic use beyond that of oral medications
* Patient discharge status is known to be to care facility
Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Slocum Center for Orthopedics and Sports Medicine

OTHER

Sponsor Role collaborator

Slocum Research & Education Foundation

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Nicholas Strasser

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nicholas L Strasser, MD

Role: PRINCIPAL_INVESTIGATOR

Slocum Center for Orthopedics and Sports Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Slocum Research & Education Foundation

Eugene, Oregon, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Erin C Owen, PhD

Role: CONTACT

541.868.3232

Michelle Bremer, BS

Role: CONTACT

5418683217

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Erin C Owen, PhD

Role: primary

541-868-3232

Michelle Bremer, BS

Role: backup

5418683217

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NLS_TAA1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Periarticular Injection Versus Popliteal Block
NCT04575688 ENROLLING_BY_INVITATION PHASE4
ESPB vs iPACK+ACB in Total Knee Arthroplasty
NCT06302218 NOT_YET_RECRUITING PHASE4
Achilles Pain Block
NCT03316378 COMPLETED PHASE2/PHASE3
Pain Relief After PrimaryTKA
NCT05751421 UNKNOWN PHASE3
Exparel vs Exparel Plus ACB in TKAs
NCT02365727 WITHDRAWN PHASE4